<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712136</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19-0554</org_study_id>
    <nct_id>NCT04712136</nct_id>
  </id_info>
  <brief_title>Healthy-related Quality of Life and Physical Activity of Children With Cardiac Malformations</brief_title>
  <acronym>QUALIMYORYTHM</acronym>
  <official_title>Healthy-related Quality of Life and Physical Activity of Children With Inherited Cardiac Arrhythmia or Inherited Cardiomyopathies: the Prospective Multicentre Controlled QUALIMYORYTHM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St-Pierre Institute, Palavas-Les-Flots</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The QUALIMYORYTHM trial is a multicentre controlled study, aiming to assess health-related&#xD;
      quality of life (HRQoL) of 107 children aged 6 to 18 years old with inherited cardiac&#xD;
      arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular&#xD;
      tachycardia, or arrhythmogenic right ventricular dysplasia), or inherited cardiomyopathies&#xD;
      (hypertrophic, dilated, or restrictive cardiomyopathy), and to compare the results to those&#xD;
      of 107 age and gender-matched healthy subjects. The secondary objective is to assess, in this&#xD;
      population, the HRQoL according to disease characteristics, level of physical activity,&#xD;
      exercise capacity, and socio-demographic data. Participants will wear a fitness tracker for 2&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advances in paediatric cardiology has improved the prognosis of children with inherited&#xD;
      cardiac disorders. However, quality of life and physical activity have been scarcely analysed&#xD;
      in children with inherited cardiac arrhythmia or inherited cardiomyopathies. Moreover,&#xD;
      current guidelines on the eligibility of young athletes with inherited cardiac disorders for&#xD;
      sports participation mainly rely on expert opinions and remain controversial.&#xD;
&#xD;
      The QUALIMYORYTHM trial is a multicentre controlled study. The main objective is to compare&#xD;
      health-related quality of life (HRQoL) of children aged 6 to 18 years old with inherited&#xD;
      cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic&#xD;
      ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or inherited&#xD;
      cardiomyopathies (hypertrophic, dilated, or restrictive cardiomyopathy), to that of age and&#xD;
      gender-matched healthy subjects. The secondary objective is to assess, in this population,&#xD;
      HRQoL according to the disease clinical and genetic characteristics, the level of physical&#xD;
      activity and motivation for sports, the exercise capacity (VO2max), and the socio-demographic&#xD;
      data. Participants will wear a fitness tracker (actimeter watch) for 2 weeks. A total of 214&#xD;
      children are required to observe a significant difference of 7 ± 15 points in the PedsQL,&#xD;
      with a power of 90% and an alpha risk of 5%.&#xD;
&#xD;
      The QUALIMYORYTHM trial intends to improve the level of evidence for future guidelines on&#xD;
      sports eligibility in this population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total score of health-reported quality of life self questionnaire</measure>
    <time_frame>baseline (1 day)</time_frame>
    <description>PedsQL questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The metabolic equivalent of task</measure>
    <time_frame>during 14 days after inclusion</time_frame>
    <description>measured by the wearable actimeter device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical activity level</measure>
    <time_frame>baseline (1 day)</time_frame>
    <description>Ricci and Gagnon questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motivation towards health-oriented physical activity</measure>
    <time_frame>baseline (1 day)</time_frame>
    <description>EMAPS motivation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>baseline (1 day)</time_frame>
    <description>Cardiopulmonary exercise test with VO2max assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial morphologic assessment</measure>
    <time_frame>baseline (1 day)</time_frame>
    <description>cardiac MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Long QT Syndrome</condition>
  <condition>Brugada Syndrome</condition>
  <condition>Catecholaminergic Polymorphic Ventricular Tachycardia</condition>
  <condition>Arrhythmogenic Right Ventricular Dysplasia</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Dilated Cardiomyopathy</condition>
  <condition>Restrictive Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Cardiac disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children aged of 6 to 18 years old with an inherited cardiac arrhythmia (long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic right ventricular dysplasia), or those with an inherited cardiomyopathy (hypertrophic, dilated, or restrictive cardiomyopathy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Children aged 6 to 18 years old referred to the paediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI cardiac</description>
    <arm_group_label>Cardiac disease</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 6 to 18 years old.&#xD;
&#xD;
          -  Group 1: Patients with an inherited cardiac arrhythmia (long QT syndrome, Brugada&#xD;
             syndrome, catecholaminergic polymorphic ventricular tachycardia, or arrhythmogenic&#xD;
             right ventricular dysplasia), or those with an inherited cardiomyopathy (hypertrophic,&#xD;
             dilated, or restrictive cardiomyopathy).&#xD;
&#xD;
          -  Group 2: Children with a completely normal check-up, referred to the paediatric&#xD;
             cardiology consultation for a non-severe functional symptom linked to exercise&#xD;
             (murmur, palpitation, or dyspnoea) or for a medical sports certificate.&#xD;
&#xD;
          -  Informed consent of parents or legal guardians, and oral assent of children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are not able to understand or fill out the questionnaires (QoL, physical&#xD;
             activity and motivation questionnaires).&#xD;
&#xD;
          -  Absolute contraindications for CPET: fever, uncontrolled asthma, respiratory failure,&#xD;
             acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or&#xD;
             haemodynamic compromise, uncontrolled heart failure, acute pulmonary embolus or&#xD;
             pulmonary infarction, and children with mental impairment leading to inability to&#xD;
             cooperate.&#xD;
&#xD;
          -  Group 2: Children with any chronic disease, medical condition (cardiac, neurologic,&#xD;
             respiratory, muscular, or renal), or medical treatment and those requiring any further&#xD;
             specialized medical consultation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pascal AMEDRO, MD</last_name>
    <phone>0467336632</phone>
    <email>p-amedro@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal AMEDRO, PhD</last_name>
      <phone>+33 (0) 4 67 33 66 39</phone>
      <email>p-amedro@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Life quality</keyword>
  <keyword>Physical activity</keyword>
  <keyword>Paediatric cardiology</keyword>
  <keyword>Inherited cardiac arrhythmia</keyword>
  <keyword>Genetic cardiomyopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
    <mesh_term>Cardiomyopathy, Restrictive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

